Q
Qian Zhou
Researcher at AbbVie
Publications - 62
Citations - 1424
Qian Zhou is an academic researcher from AbbVie. The author has contributed to research in topics: Crohn's disease & Adalimumab. The author has an hindex of 14, co-authored 49 publications receiving 1027 citations. Previous affiliations of Qian Zhou include University of Oxford.
Papers
More filters
Journal ArticleDOI
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
Jean-Frederic Colombel,Remo Panaccione,Peter Bossuyt,Milan Lukas,Filip Baert,Tomáš Vaňásek,Ahmet Danalioglu,Gottfried Novacek,Alessandro Armuzzi,Xavier Hébuterne,Simon Travis,Silvio Danese,Walter Reinisch,William J. Sandborn,Paul Rutgeerts,Daniel W. Hommes,Stefan Schreiber,Ezequiel Neimark,Bidan Huang,Qian Zhou,Paloma Mendez,J Petersson,Kori Wallace,Anne M. Robinson,Roopal Thakkar,Geert R. D'Haens +25 more
TL;DR: This trial aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients management with a clinical management algorithm.
Journal ArticleDOI
Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease
William J. Sandborn,Brian G. Feagan,Edward V. Loftus,Laurent Peyrin-Biroulet,Gert Van Assche,Geert R. D'Haens,Stefan Schreiber,Jean-Frederic Colombel,James D. Lewis,Subrata Ghosh,Alessandro Armuzzi,Ellen Scherl,Hans H Herfarth,Lauren Vitale,Mohamed-Eslam F. Mohamed,Ahmed A. Othman,Qian Zhou,Bidan Huang,Roopal Thakkar,Aileen L. Pangan,Ana P. Lacerda,Julián Panés +21 more
TL;DR: Upadacitinib's benefit-risk profile supports further development for treatment of CD and induced endoscopic remission in a significant proportion of patients, compared with placebo.
Journal ArticleDOI
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
Remo Panaccione,Jean-Frederic Colombel,W J Sandborn,G. D'Haens,Qian Zhou,Paul F. Pollack,Roopal Thakkar,Anne M. Robinson +7 more
TL;DR: Stable remission rates have been demonstrated for up to 2 years in adalimumab‐treated patients with moderately to severely active Crohn's disease enrolled in the CHARM and ADHERE clinical trials.
Journal ArticleDOI
Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest
William J. Sandborn,Brian G. Feagan,Julián Panés,Geert R. D'Haens,Jean-Frederic Colombel,Qian Zhou,Bidan Huang,Jeffrey Enejosa,Aileen L. Pangan,Ana P. Lacerda +9 more
Journal ArticleDOI
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab.
Mark T. Osterman,William J. Sandborn,Jean-Frederic Colombel,Laurent Peyrin-Biroulet,Anne M. Robinson,Qian Zhou,James D. Lewis +6 more
TL;DR: Higher disease activity in CD is associated with significantly increased risks of both serious and opportunistic infections, and consideration should be given to expanding herpes zoster vaccination guidelines to include younger patients.